Human recombinant factor IX: Safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates

Blood

Volumn 98, Issue 13, 2001, Pages 3600-3606

  Roth, David A ^a,b,c,d,e   Kessler, Craig M ^a,b,c,d   John Pasi, K ^a,b,c,d   Rup, Bonita ^a,b,c,d   Courter, Suzanne G ^a,b,c,d   Tubridy, Karen L ^a,b,c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d PFIZER INC   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; FIBRINOPEPTIDE A; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HEMOPHILIA B; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; THROMBOGENICITY; VIRUS TRANSMISSION;

EID: 0035895058     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.13.3600     Document Type: Article

References (39)

1. Roberts H, Eberst ME. Current management of hemophilia B. Hematol Oncol Clin North Am. 1993;7:1269-1280.
2. Lozier JN, Kessler CM. Clinical aspects and therapy of hemophilia. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone; 2000:1883-1904.
3. Thompson AR. Factor IX concentrates for clinical use. Semin Thromb Hemost. 1993;19:25-36.
4. Cuthbert RJG, Ludlam CA, Steel CM, Beatson D, Peutherer JF. Immunological studies in H IV seronegative haemophiliacs: relationships to blood product therapy. Br J Haematol. 1992;80:364-369.
5. Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol. 1991;28:3-5.
6. Guidance for industry: revised precautionary measures to reduce the possible risk of transmission of Creutzfeldt-Jakob Disease (CJD) and new variant Creutzfeldt-Jakob Disease (nvCJD) by blood and blood products. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER); November 1999.
7. Brown P, Will RG, Bradley R, Asher DM, Detwiler L. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob Disease: background, evolution, and current concerns. Emerg Infect Dis. 2001;7:6-16.
8. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347:921-925.
9. Evatt BL. Prions and haemophilia: assessment of risk. Haemophilia. 1998;4:628-633.
10. Vermylen J, Peerlinck K. Review of the hepatitis A epidemics in hemophiliacs in Europe. Vox Sang. 1994;67(suppl 4):8-11.
11. Mariani G, Di Paolantonio T, Baklaya R, Morfini M, Mannucci PM, and the Ad Hoc Study Group of the Fondzaione dell 'Emofilia. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. Transfusion. 1993;33:814-818.
12. Bartolomei Corsi O, Azzi A, Morfini M, Fanci R, Rossi Ferrini P. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates. J Med Virol. 1988;25:165-170.
13. Yee TT, Cohen BJ, Pasi KJ, Lee CA. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol. 1996;93:457-459.
14. Flores G, Juarez JC, Montoro JB, et al. Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses. Haemophilia. 1995;1:115-117.
15. Choo KH, Gould KG, Rees DJ, Brownlee GG. Molecular cloning of the gene for human anti-haemophilic factor IX. Nature. 1982;299:178-180.
16. Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of γ-carboxyglutamic acid. Blood. 1999;93:1798-1808.
17. Harrison S, Adamson S, Bonam D, et al. The manufacturing process for recombinant factor IX. Semin Hematol. 1998;35(suppl 2):4-10.
18. Bush L, Webb C, Bartlett L, et al. The formulation of recombinant factor IX: stability, robustness, and convenience. Semin Hematol. 1998;35(suppl 2):18-21.
19. Kaufman RJ, Wasley LC, Furie BC, Furie B, Shoemaker CB. Expression, purification, and characterization of recombinant γ-carboxylated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem. 1986;261:9622-9628.
20. Wasley LC, Rehemtulla A, Bristol JA, Kaufman RJ. PACE/Furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway. J Biol Chem. 1993;268:8458-8465.
21. White G, Shapiro A, Ragni M, et al. Clinical evaluation of recombinant factor IX. Semin Hematol. 1998;35(suppl 2):33-38.
22. Bond M, Jankowski M, Patei H, et al. Biochemical characterization of recombinant factor IX. Semin Hematol. 1998;35(suppl 2):11-17.
23. Bond MD, Huberty MC, Jankowski MA, et al. Identification of O-glycosylation, sulfation and phosphorylation sites in the activation peptide of human plasma factor IX. Blood. 1994;84(suppl 1):531a.
24. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost. 1997;78:261-265.
25. White GC II, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE, Group MS. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. Thromb Haemost. 1995;73:779-784.
26. Shapiro AD, Ragni MV, Lusher JM, et al. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. Thromb Haemost. 1996;75:30-35.
27. Djulbegovic B, Marasa M, Pesto A, et al. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B. Am J Hematol. 1996;51:168-170.
28. Warrier I, Kasper CK, White GC, Shapiro AD, Bergman GE. Safety of high doses of a monoclonal antibody-purified factor IX concentrate. Am J Hematol. 1995;49:92-94.
29. Kim HC, McMillan CW, White GC, Bergman GE, Horton MW, Saidi P. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood. 1992;79:568-575.
30. Shapiro AD, White IGC, Kim HC, Lusher JM, Bergman GE, The Mononine® Study Group. Efficacy and safety of monoclonal antibody purified factor IX concentrate in haemophilia B patients undergoing surgical procedures. Haemophilia. 1997;3:247-253.
31. White GC, Courter S, Bray GL, Lee M, Gomperts ED. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. Thromb Haemost. 1997;77:660-667.
32. Sultan Y, Group TFHS. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost. 1992;67:600-602.
33. Katz J. Prevalence of factor IX inhibitors among patients with hemophilia B: results of a large-scale North American survey. Haemophilia. 1996;2:28-31.
34. Giannelli F, Choo KH, Rees DJ, et al. Gene deletions in patients with haemophilia B and antifactor IX antibodies. Nature. 1983;303:181-182.
35. Matsushita T, Tanimoto M, Yamamoto K, et al. DNA sequence analysis of three inhibitor-positive hemophilia B patients without gross gene deletion: identification of four novel mutations in factor IX gene. J Lab Clin Med. 1990;116:492-497.
36. Ljung RC. Gene mutations and inhibitor formation in patients with hemophilia B. Acta Haematol. 1995;94:49-52.
37. Thorland EC, Drost JB, Lusher JM, et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia. 1999;5:101-105.
38. Houston F, Foster JD, Chong A, Hunter N, Bostock CJ. Transmission of BSE by blood transfusion in sheep. Lancet. 2000;356:999-1000.
39. Fisher MB, Roeckl C, Parizek P, Schwarz HP, Aguzzi A. Binding of disease-associated prion protein to plasminogen. Nature. 2000;408:479-483.